Intelligence Feed event · Equity · 2026-08-28

    Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim

    Question

    Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim

    Direct answer

    Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim”, revision 1, evidence through 2026-08-28. https://marketontology.com/market-events/2026-08-28/biohaven-signs-795m-licensing-deal-with-sk-biopharm-for-opakalim-797159

    EQUITY
    Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
    Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
    BHVNXBI
    Impact
    73
    AUG 28
    SIG
    86%
    BHVNXBI
    Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
    Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
    → Milestone licensing commitments of up to $795M inject non-dilutive capital into BHVN, reducing cash burn and funding clinical pipeline progression.
    Impact
    Biohaven announced a worldwide licensing agreement with SK Biopharmaceuticals with total potential deal value reaching $795 million. The collaboration grants exclusive global rights to Biohaven's Kv7 ion channel platform and lead asset opakalim for treating focal epilepsy. The structure provides upfront and contingent development and commercial milestone payments. Separately, Biohaven and partner Yale University secured a $4 million legal judgment.
    Affected
    BHVNXBI
    Transmission
    Milestone licensing commitments of up to $795M inject non-dilutive capital into BHVN, reducing cash burn and funding clinical pipeline progression.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BHVNnon-dilutive funding influx through $795M licensing agreementUp1-5dSigned up to $795 million global licensing agreement with SK Biopharmaceuticals.
    XBIbiotech licensing deal momentum and balance sheet de-riskingUp1-4wValidates commercial interest in central nervous system ion channel pipelines.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed162.38 2026-08-28+0.07%+0.88%-3.55%

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month